Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 3/20 | 0.53 |
| ▸ | ESRRA | P11474 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15305094 | 0.93 | KDM4E (0.49) | ESR2ESRRAKDM4EALDH1A1PTPN11 | |
| SCHEMBL2594824 | 0.92 | ESRRA (0.45) | ESR2ESRRAKDM4EALDH1A1PTPN11 | |
| SCHEMBL14924033 | 0.90 | ALDH1A1 (0.47) | ESR2ESRRAKDM4EALDH1A1PTPN11 | |
| SCHEMBL3063674 | 0.89 | NPBWR1 (0.42) | ESR2ESRRAKDM4EALDH1A1PTPN11 | |
| SCHEMBL13097219 | 0.82 | ESRRA (0.48) | ESR2ESRRAKDM4EALDH1A1TP53 | |
| SCHEMBL2588516 | 0.82 | EGFR (0.51) | KDM4EALDH1A1PTPN11KMT2ATP53 | |
| SCHEMBL2594823 | 0.80 | ESR2 (0.39) | ESR2ESRRAKDM4EALDH1A1PTPN11 | |
| SCHEMBL15026341 | 0.79 | PTPN11 (0.41) | ESR2ESRRAKDM4EALDH1A1PTPN11 | |
| SCHEMBL15026343 | 0.78 | ESRRA (0.41) | ESR2ESRRAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL13087226 | 0.77 | ESR2 (0.66) | ESR2ESRRAKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9623021-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9623021-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9623021-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9604931-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604931-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2017-01-19 | — | — | US | disclosed |
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2017-01-19 | — | — | US | disclosed |
| US-9078888-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9078888-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9078888-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | DALTON JAMES T (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2011140228-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| EP-2106212-A2 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, Inc. (US) | 2009-10-07 | — | — | EP | disclosed |
| US-20090030036-A1 | Nuclear receptor binding agents | GTX, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030036-A1 | Nuclear receptor binding agents | GTX, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030036-A1 | Nuclear receptor binding agents | GTX, INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2008091555-A2 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | ESRRB, ESRRG, ESRRA | ESR2 4/4885ESRRA 3/4885KDM4E 1789/4885 |
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | AKR1C3, AKR1C1, AKR1C2 | ESR2 511/4885ESRRA 90/4885KDM4E 901/4885 |
| US-20090030036-A1 | Nuclear receptor binding agents | NR0B1, NR2E3, NR0B2 | ESR2 22/4885ESRRA 4/4885KDM4E 4528/4885 |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | FABP1, FABP4, ADIPOR2 | ESR2 16/4885ESRRA 11/4885KDM4E 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.